×
  • Select the area you would like to search.
  • ACTIVE INVESTIGATIONS Search for current projects using the investigator's name, institution, or keywords.
  • EXPERTS KNOWLEDGE BASE Enter keywords to search a list of questions and answers received and processed by the ADNI team.
  • ADNI PDFS Search any ADNI publication pdf by author, keyword, or PMID. Use an asterisk only to view all pdfs.

ADNI2

Participant Pool:
  • 150 Normal Controls (new)
  • 450-500 CN and MCI (rollover from ADNI1; approximate)
  • 150 EMCI (new)
  • 200 EMCI (rollover from ADNI GO; approximate)
  • 150 LMCI (new)
  • 200 mild AD (new)
Objectives:
  1. Determine the relationships among clinical, imaging, genetic, and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD) as the pathology evolves.
  2. Inform the neuroscience of AD, identify diagnostic and prognostic markers and outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios.
  3. Develop uniform standards for acquiring longitudinal multisite MRI and PET data on patients with AD, MCI, and elderly controls.
  4. Perform longitudinal clinical, cognitive, MRI, PET (18F-Florbetapir and FDG), and blood and CSF biomarker studies on 550 newly enrolled subjects in addition to continuing these studies for approximately 700 subjects from ADNI1 and ADNI GO for an additional 5 years.
  5. Collect blood samples for DNA and RNA extraction. Newly enrolled subjects will also have samples collected for Cell Immortalization and APOE genotyping.
  6. Validate the clinical diagnoses and imaging and biomarker surrogates through neuropathological examination of ADNI1, ADNI GO, and ADNI2 participants who come to autopsy.